JP6735277B2 - 乳癌療法剤に対する反応を予測するための方法および乳癌の処置の方法 - Google Patents
乳癌療法剤に対する反応を予測するための方法および乳癌の処置の方法 Download PDFInfo
- Publication number
- JP6735277B2 JP6735277B2 JP2017531209A JP2017531209A JP6735277B2 JP 6735277 B2 JP6735277 B2 JP 6735277B2 JP 2017531209 A JP2017531209 A JP 2017531209A JP 2017531209 A JP2017531209 A JP 2017531209A JP 6735277 B2 JP6735277 B2 JP 6735277B2
- Authority
- JP
- Japan
- Prior art keywords
- basal
- luminal
- breast cancer
- classifier score
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 172
- 208000026310 Breast neoplasm Diseases 0.000 title claims description 156
- 206010006187 Breast cancer Diseases 0.000 title claims description 148
- 230000004044 response Effects 0.000 title description 72
- 239000012830 cancer therapeutic Substances 0.000 title 1
- 108010080146 androgen receptors Proteins 0.000 claims description 217
- 208000026535 luminal A breast carcinoma Diseases 0.000 claims description 191
- 239000003112 inhibitor Substances 0.000 claims description 177
- 238000011282 treatment Methods 0.000 claims description 172
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical group C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 claims description 133
- 229960004671 enzalutamide Drugs 0.000 claims description 132
- 230000014509 gene expression Effects 0.000 claims description 92
- 238000002560 therapeutic procedure Methods 0.000 claims description 90
- 210000004027 cell Anatomy 0.000 claims description 87
- 239000000523 sample Substances 0.000 claims description 81
- 239000012472 biological sample Substances 0.000 claims description 70
- 108090000623 proteins and genes Proteins 0.000 claims description 70
- 210000001519 tissue Anatomy 0.000 claims description 49
- 229930012538 Paclitaxel Natural products 0.000 claims description 45
- 229960001592 paclitaxel Drugs 0.000 claims description 45
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 45
- 239000003814 drug Substances 0.000 claims description 38
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 29
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 28
- -1 aleprolid Chemical compound 0.000 claims description 27
- 238000012360 testing method Methods 0.000 claims description 23
- 238000003556 assay Methods 0.000 claims description 18
- 239000002775 capsule Substances 0.000 claims description 18
- 229940124597 therapeutic agent Drugs 0.000 claims description 18
- 108010000817 Leuprolide Proteins 0.000 claims description 17
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 17
- 229960004338 leuprorelin Drugs 0.000 claims description 17
- 229940127084 other anti-cancer agent Drugs 0.000 claims description 17
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 16
- 210000001124 body fluid Anatomy 0.000 claims description 16
- 239000010839 body fluid Substances 0.000 claims description 15
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 14
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 13
- 238000001574 biopsy Methods 0.000 claims description 13
- 229960002949 fluorouracil Drugs 0.000 claims description 13
- 210000000481 breast Anatomy 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 239000002246 antineoplastic agent Substances 0.000 claims description 10
- 210000004881 tumor cell Anatomy 0.000 claims description 10
- 229960004528 vincristine Drugs 0.000 claims description 9
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 9
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 9
- 210000002751 lymph Anatomy 0.000 claims description 8
- 229960004857 mitomycin Drugs 0.000 claims description 8
- 210000002445 nipple Anatomy 0.000 claims description 8
- 210000003296 saliva Anatomy 0.000 claims description 8
- 210000002700 urine Anatomy 0.000 claims description 8
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 7
- 229960001603 tamoxifen Drugs 0.000 claims description 7
- 229960000575 trastuzumab Drugs 0.000 claims description 7
- 229960003048 vinblastine Drugs 0.000 claims description 7
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 7
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 claims description 6
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims description 6
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 6
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 6
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims description 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 6
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 6
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims description 6
- 229940123237 Taxane Drugs 0.000 claims description 6
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 6
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims description 6
- 229940062527 alendronate Drugs 0.000 claims description 6
- 229960004562 carboplatin Drugs 0.000 claims description 6
- 190000008236 carboplatin Chemical compound 0.000 claims description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 6
- 229960004316 cisplatin Drugs 0.000 claims description 6
- 229960004397 cyclophosphamide Drugs 0.000 claims description 6
- 229960001251 denosumab Drugs 0.000 claims description 6
- 229960003668 docetaxel Drugs 0.000 claims description 6
- 229960000255 exemestane Drugs 0.000 claims description 6
- 229960002258 fulvestrant Drugs 0.000 claims description 6
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 6
- 229960005277 gemcitabine Drugs 0.000 claims description 6
- 229940015872 ibandronate Drugs 0.000 claims description 6
- 229960004768 irinotecan Drugs 0.000 claims description 6
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 6
- 229960002014 ixabepilone Drugs 0.000 claims description 6
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 claims description 6
- 229960003881 letrozole Drugs 0.000 claims description 6
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 6
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims description 6
- 229960004296 megestrol acetate Drugs 0.000 claims description 6
- 229960000485 methotrexate Drugs 0.000 claims description 6
- 229940046231 pamidronate Drugs 0.000 claims description 6
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims description 6
- 229960004622 raloxifene Drugs 0.000 claims description 6
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 6
- 229940089617 risedronate Drugs 0.000 claims description 6
- 229960004964 temozolomide Drugs 0.000 claims description 6
- 229960001196 thiotepa Drugs 0.000 claims description 6
- 229960000303 topotecan Drugs 0.000 claims description 6
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 6
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims description 6
- 229960005026 toremifene Drugs 0.000 claims description 6
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 6
- 229960002066 vinorelbine Drugs 0.000 claims description 6
- 229960004276 zoledronic acid Drugs 0.000 claims description 6
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 6
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 5
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 5
- 229960000397 bevacizumab Drugs 0.000 claims description 5
- 229960004117 capecitabine Drugs 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 229960002932 anastrozole Drugs 0.000 claims description 4
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 4
- 229960003649 eribulin Drugs 0.000 claims description 3
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 claims description 3
- 102000001307 androgen receptors Human genes 0.000 claims 14
- 102100032187 Androgen receptor Human genes 0.000 description 203
- 206010028980 Neoplasm Diseases 0.000 description 51
- 230000004083 survival effect Effects 0.000 description 45
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 22
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 22
- 238000003364 immunohistochemistry Methods 0.000 description 21
- 229940079593 drug Drugs 0.000 description 20
- 239000013610 patient sample Substances 0.000 description 19
- 238000003745 diagnosis Methods 0.000 description 18
- 102000015694 estrogen receptors Human genes 0.000 description 18
- 108010038795 estrogen receptors Proteins 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 201000010099 disease Diseases 0.000 description 16
- 102000003998 progesterone receptors Human genes 0.000 description 16
- 108090000468 progesterone receptors Proteins 0.000 description 16
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 13
- 229960000997 bicalutamide Drugs 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 13
- OZPFIJIOIVJZMN-SFHVURJKSA-N 6-[(7s)-7-hydroxy-5,6-dihydropyrrolo[1,2-c]imidazol-7-yl]-n-methylnaphthalene-2-carboxamide Chemical compound C1=CC2=CC(C(=O)NC)=CC=C2C=C1[C@]1(O)C2=CN=CN2CC1 OZPFIJIOIVJZMN-SFHVURJKSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 230000008901 benefit Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000004043 responsiveness Effects 0.000 description 12
- 230000002596 correlated effect Effects 0.000 description 11
- 208000026534 luminal B breast carcinoma Diseases 0.000 description 11
- 238000010186 staining Methods 0.000 description 11
- PAFKTGFSEFKSQG-PAASFTFBSA-N Galeterone Chemical compound C1=NC2=CC=CC=C2N1C1=CC[C@H]2[C@H](CC=C3[C@@]4(CC[C@H](O)C3)C)[C@@H]4CC[C@@]21C PAFKTGFSEFKSQG-PAASFTFBSA-N 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 238000003559 RNA-seq method Methods 0.000 description 8
- 230000002035 prolonged effect Effects 0.000 description 8
- 230000036961 partial effect Effects 0.000 description 7
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 6
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 description 6
- 229960004103 abiraterone acetate Drugs 0.000 description 6
- HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 description 6
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 6
- 229960000978 cyproterone acetate Drugs 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 6
- 229960004039 finasteride Drugs 0.000 description 6
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 6
- 229960002074 flutamide Drugs 0.000 description 6
- 229960004125 ketoconazole Drugs 0.000 description 6
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 6
- 229960002653 nilutamide Drugs 0.000 description 6
- 229950004023 orteronel Drugs 0.000 description 6
- 206010061818 Disease progression Diseases 0.000 description 5
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 5
- 108010069236 Goserelin Proteins 0.000 description 5
- 229960002184 abarelix Drugs 0.000 description 5
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 5
- 108010023617 abarelix Proteins 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 230000005750 disease progression Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 229960002913 goserelin Drugs 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000010606 normalization Methods 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- YVXVTLGIDOACBJ-SFHVURJKSA-N (2S)-3-(4-acetamidophenoxy)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide Chemical compound C1=CC(NC(=O)C)=CC=C1OC[C@](C)(O)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 YVXVTLGIDOACBJ-SFHVURJKSA-N 0.000 description 4
- 238000010195 expression analysis Methods 0.000 description 4
- 238000003633 gene expression assay Methods 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229940123407 Androgen receptor antagonist Drugs 0.000 description 3
- 206010055113 Breast cancer metastatic Diseases 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 101150029707 ERBB2 gene Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000011789 NOD SCID mouse Methods 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000013145 classification model Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 238000003305 oral gavage Methods 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- PCKNFPQPGUWFHO-UQRQXUALSA-N (E)-flucycloxuron Chemical compound FC1=CC=CC(F)=C1C(=O)NC(=O)NC(C=C1)=CC=C1CO\N=C(C=1C=CC(Cl)=CC=1)/C1CC1 PCKNFPQPGUWFHO-UQRQXUALSA-N 0.000 description 2
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 2
- 108010037003 Buserelin Proteins 0.000 description 2
- 229940124766 Cyp17 inhibitor Drugs 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 2
- 102000005705 Keratin-5 Human genes 0.000 description 2
- 108010070553 Keratin-5 Proteins 0.000 description 2
- 102000005706 Keratin-6 Human genes 0.000 description 2
- 108010070557 Keratin-6 Proteins 0.000 description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 2
- 229960002719 buserelin Drugs 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012758 nuclear staining Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 108091006082 receptor inhibitors Proteins 0.000 description 2
- 238000009094 second-line therapy Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000011125 single therapy Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 229940094060 tykerb Drugs 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101150052384 50 gene Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010072813 Breast angiosarcoma Diseases 0.000 description 1
- 201000011057 Breast sarcoma Diseases 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000011460 HER2-targeted therapy Methods 0.000 description 1
- 241000023320 Luma <angiosperm> Species 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000003936 androgen receptor antagonist Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 208000010572 basal-like breast carcinoma Diseases 0.000 description 1
- 229940029072 bicalutamide 150 mg Drugs 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000014581 breast ductal adenocarcinoma Diseases 0.000 description 1
- 201000003714 breast lobular carcinoma Diseases 0.000 description 1
- 201000009613 breast lymphoma Diseases 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
- 238000007387 excisional biopsy Methods 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229950003400 galeterone Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 230000004547 gene signature Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011332 tumor tissue staining Methods 0.000 description 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
- 229940085728 xtandi Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462091195P | 2014-12-12 | 2014-12-12 | |
| US62/091,195 | 2014-12-12 | ||
| US201562142504P | 2015-04-03 | 2015-04-03 | |
| US62/142,504 | 2015-04-03 | ||
| US201562167110P | 2015-05-27 | 2015-05-27 | |
| US62/167,110 | 2015-05-27 | ||
| PCT/US2015/064500 WO2016094408A1 (en) | 2014-12-12 | 2015-12-08 | Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018504892A JP2018504892A (ja) | 2018-02-22 |
| JP2018504892A5 JP2018504892A5 (https=) | 2019-01-24 |
| JP6735277B2 true JP6735277B2 (ja) | 2020-08-05 |
Family
ID=55273509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017531209A Expired - Fee Related JP6735277B2 (ja) | 2014-12-12 | 2015-12-08 | 乳癌療法剤に対する反応を予測するための方法および乳癌の処置の方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10196693B2 (https=) |
| EP (2) | EP3604556A1 (https=) |
| JP (1) | JP6735277B2 (https=) |
| KR (1) | KR20170095306A (https=) |
| CN (1) | CN107109488A (https=) |
| AU (1) | AU2015360767A1 (https=) |
| BR (1) | BR112017012142A2 (https=) |
| CA (1) | CA2970469A1 (https=) |
| ES (1) | ES2748005T3 (https=) |
| IL (1) | IL252587A0 (https=) |
| MX (1) | MX2017007707A (https=) |
| RU (1) | RU2017120330A (https=) |
| SG (1) | SG11201704425TA (https=) |
| WO (1) | WO2016094408A1 (https=) |
| ZA (1) | ZA201703904B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2843417C (en) | 2011-07-29 | 2018-08-21 | Medivation Prostate Therapeutics, Inc. | Treatment of breast cancer |
| US20140243211A1 (en) | 2013-02-28 | 2014-08-28 | Indiana University Research & Technology Corporation | Blood biomarkers for suicidality |
| CN107109488A (zh) * | 2014-12-12 | 2017-08-29 | 麦迪韦逊前列腺治疗股份有限公司 | 预测对乳腺癌治疗剂的反应的方法和治疗乳腺癌的方法 |
| WO2016201299A1 (en) | 2015-06-12 | 2016-12-15 | Indiana University Research & Technology Corporation | Predicting suicidality using a combined genomic and clinical risk assessment |
| KR101966493B1 (ko) * | 2016-06-27 | 2019-04-05 | 국립암센터 | 삼중음성유방암 예후 예측용 바이오마커 |
| KR101896558B1 (ko) * | 2016-11-21 | 2018-09-07 | 주식회사 젠큐릭스 | 유방암 환자의 예후 예측 방법 |
| CN110573958A (zh) * | 2017-04-26 | 2019-12-13 | 日本电信电话株式会社 | N×n光开关 |
| EP3635130A4 (en) | 2017-05-12 | 2021-06-09 | Indiana University Research and Technology Corporation | Precision medicine for treating and preventing suicidality |
| RU2648523C1 (ru) * | 2017-05-22 | 2018-03-26 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") | Способ прогнозирования исхода заболевания у больных люминальным в и трижды негативным раком молочной железы у пациенток, не получавших в неоадъювантном режиме химио- или гормонотерапию |
| KR102542275B1 (ko) * | 2018-05-14 | 2023-06-12 | 하이노바 파마슈티컬스 인코포레이티드 | Hc-1119 제제 및 그 제조방법 및 용도 |
| WO2020001473A1 (zh) * | 2018-06-28 | 2020-01-02 | 复旦大学 | 小核仁核糖核酸snord33作为生物标记物用于制备检测试剂盒中的用途 |
| CN109735625A (zh) * | 2019-03-18 | 2019-05-10 | 马榕 | 乳头溢液在检测肿瘤相关基因中的应用 |
| CN114334000B (zh) * | 2021-12-28 | 2025-07-25 | 上海中医药大学 | 基于转录组图谱的组合药物生成方法、系统及存储介质 |
| US20260043086A1 (en) * | 2022-08-06 | 2026-02-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Predictive biomarker in avastin in colon cancer |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM |
| DE69829402T2 (de) | 1997-10-31 | 2006-04-13 | Affymetrix, Inc. (a Delaware Corp.), Santa Clara | Expressionsprofile in adulten und fötalen organen |
| US6020135A (en) | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
| US6937713B1 (en) | 1999-12-30 | 2005-08-30 | At&T Corp. | IP call forward profile |
| US7504222B2 (en) | 2001-10-31 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| US20070192880A1 (en) | 2003-10-03 | 2007-08-16 | University Of Rochester | Horming response element binding transregulators |
| US20070059720A9 (en) | 2004-12-06 | 2007-03-15 | Suzanne Fuqua | RNA expression profile predicting response to tamoxifen in breast cancer patients |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| NZ564223A (en) | 2005-05-13 | 2011-03-31 | Univ California | Diarylhydantoin compounds for treating hormone refractory prostate cancer |
| EP1954708A4 (en) | 2005-11-23 | 2009-05-13 | Univ Utah Res Found | Methods and compositions involving intrinsic genes |
| SI2656842T1 (sl) | 2006-03-27 | 2016-10-28 | The Regents Of The University Of California | Modulator androgenih receptorjev za zdravljenje raka prostate in bolezni, povezanih z androgenimi receptorji |
| WO2007127010A2 (en) | 2006-03-29 | 2007-11-08 | The Regents Of The University Of California | Diarylthiohydantoin compounds |
| EP2620432A3 (en) | 2007-10-26 | 2013-12-18 | The Regents Of the University of California | Diarylhydantoin compounds |
| US7732491B2 (en) * | 2007-11-12 | 2010-06-08 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| US8450290B2 (en) | 2007-11-26 | 2013-05-28 | Enzon Pharmaceuticals, Inc. | Methods for treating androgen receptor dependent disorders including cancers |
| WO2009114534A1 (en) | 2008-03-14 | 2009-09-17 | The Regents Of The University Of California | Multi-gene classifiers and prognostic indicators for cancers |
| ES2457534T3 (es) | 2008-05-30 | 2014-04-28 | The University Of North Carolina At Chapel Hill | Perfiles de expresión génica para predecir desenlaces en cáncer de mama |
| SG173837A1 (en) | 2009-02-24 | 2011-09-29 | Medivation Prostate Therapeutics Inc | Specific diarylhydantoin and diarylthiohydantoin compounds |
| US8710086B2 (en) | 2009-04-09 | 2014-04-29 | Medivation Technologies, Inc. | Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof |
| WO2010125117A2 (en) | 2009-04-29 | 2010-11-04 | Ralph Wirtz | A method to assess prognosis and to predict therapeutic success in cancer by determining hormone receptor expression levels |
| US8507195B2 (en) | 2009-08-20 | 2013-08-13 | The Regents Of The University Of Colorado | MiRNAs dysregulated in triple-negative breast cancer |
| JP2013504064A (ja) | 2009-09-03 | 2013-02-04 | ザ スクリプス リサーチ インスティチュート | 循環腫瘍細胞を分類する方法 |
| EP2485804A4 (en) | 2009-10-07 | 2015-07-29 | Medivation Technologies Inc | SUBSTITUTED PHENYLCARBAMOYL ALKYLAMINOAREN COMPOUNDS AND N, N'-BIS-ARYL UREA COMPOUNDS |
| EP2685988A4 (en) * | 2011-03-15 | 2014-08-20 | Univ North Carolina | Methods of treating breast cancer with anthracycline therapy |
| US8781912B2 (en) | 2011-03-15 | 2014-07-15 | Opera Solutions, Llc | Computer-based method and computer program product for setting floor prices for items sold at auction |
| CA2843417C (en) | 2011-07-29 | 2018-08-21 | Medivation Prostate Therapeutics, Inc. | Treatment of breast cancer |
| JP6144695B2 (ja) | 2011-11-30 | 2017-06-07 | ユニバーシティー オブ ノースカロライナ アット チャペル ヒル | タキサン療法を用いて乳癌を処置する方法 |
| ES2696202T3 (es) | 2012-08-23 | 2019-01-14 | Univ Colorado Regents | Método para determinar el tratamiento de cáncer de mama |
| AR092982A1 (es) * | 2012-10-11 | 2015-05-13 | Isis Pharmaceuticals Inc | Modulacion de la expresion de receptores androgenicos |
| WO2014075067A1 (en) | 2012-11-12 | 2014-05-15 | Nanostring Technologies, Inc. | Methods to predict breast cancer outcome |
| US10679730B2 (en) * | 2013-05-28 | 2020-06-09 | The University Of Chicago | Prognostic and predictive breast cancer signature |
| CN107109488A (zh) | 2014-12-12 | 2017-08-29 | 麦迪韦逊前列腺治疗股份有限公司 | 预测对乳腺癌治疗剂的反应的方法和治疗乳腺癌的方法 |
-
2015
- 2015-12-08 CN CN201580068041.7A patent/CN107109488A/zh active Pending
- 2015-12-08 KR KR1020177019159A patent/KR20170095306A/ko not_active Withdrawn
- 2015-12-08 ES ES15831013T patent/ES2748005T3/es active Active
- 2015-12-08 CA CA2970469A patent/CA2970469A1/en active Pending
- 2015-12-08 WO PCT/US2015/064500 patent/WO2016094408A1/en not_active Ceased
- 2015-12-08 US US14/962,864 patent/US10196693B2/en active Active
- 2015-12-08 SG SG11201704425TA patent/SG11201704425TA/en unknown
- 2015-12-08 EP EP19192143.6A patent/EP3604556A1/en not_active Withdrawn
- 2015-12-08 JP JP2017531209A patent/JP6735277B2/ja not_active Expired - Fee Related
- 2015-12-08 BR BR112017012142A patent/BR112017012142A2/pt not_active IP Right Cessation
- 2015-12-08 RU RU2017120330A patent/RU2017120330A/ru not_active Application Discontinuation
- 2015-12-08 EP EP15831013.6A patent/EP3230471B1/en not_active Not-in-force
- 2015-12-08 AU AU2015360767A patent/AU2015360767A1/en not_active Abandoned
- 2015-12-08 MX MX2017007707A patent/MX2017007707A/es unknown
-
2017
- 2017-05-30 IL IL252587A patent/IL252587A0/en unknown
- 2017-06-07 ZA ZA2017/03904A patent/ZA201703904B/en unknown
-
2018
- 2018-12-10 US US16/215,340 patent/US11186876B2/en active Active
-
2021
- 2021-11-10 US US17/523,235 patent/US11952634B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11186876B2 (en) | 2021-11-30 |
| WO2016094408A1 (en) | 2016-06-16 |
| US10196693B2 (en) | 2019-02-05 |
| EP3604556A1 (en) | 2020-02-05 |
| RU2017120330A (ru) | 2019-01-14 |
| RU2017120330A3 (https=) | 2019-07-24 |
| KR20170095306A (ko) | 2017-08-22 |
| AU2015360767A1 (en) | 2017-06-08 |
| EP3230471A1 (en) | 2017-10-18 |
| JP2018504892A (ja) | 2018-02-22 |
| ZA201703904B (en) | 2019-12-18 |
| ES2748005T3 (es) | 2020-03-12 |
| US20220056541A1 (en) | 2022-02-24 |
| EP3230471B1 (en) | 2019-08-28 |
| CN107109488A (zh) | 2017-08-29 |
| SG11201704425TA (en) | 2017-06-29 |
| CA2970469A1 (en) | 2016-06-16 |
| US20160168646A1 (en) | 2016-06-16 |
| BR112017012142A2 (pt) | 2018-01-02 |
| US11952634B2 (en) | 2024-04-09 |
| MX2017007707A (es) | 2018-03-06 |
| US20190169697A1 (en) | 2019-06-06 |
| IL252587A0 (en) | 2017-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6735277B2 (ja) | 乳癌療法剤に対する反応を予測するための方法および乳癌の処置の方法 | |
| RU2739942C2 (ru) | Терапевтические, диагностические и прогностические способы для рака мочевого пузыря | |
| KR102125496B1 (ko) | 파르네실전달효소 억제제를 이용하여 암환자를 치료하는 방법 | |
| KR102604025B1 (ko) | 개인별 약물 치료 계획의 개발 방법 및 단백질체 프로파일을 기반으로 하는 표적 약물 개발 방법 | |
| US20190192517A1 (en) | Treatment of squamous cell carcinomas with inhibitors of erk | |
| US20180147226A1 (en) | Methods and assays for combination treatment of cancer | |
| JP2021502071A (ja) | がんバイオマーカーおよびその使用方法 | |
| WO2013052480A1 (en) | Marker-based prognostic risk score in colon cancer | |
| CN103562406A (zh) | 用于预测对艾日布林的反应的方法和组合物 | |
| TW202023556A (zh) | 以mapk路徑抑制劑治療腺癌 | |
| JP2019534290A (ja) | 癌の治療方法において使用するためのファルネシルトランスフェラーゼ阻害剤 | |
| US20210085634A1 (en) | Methods of identifying and treating patients with hif-2 inhibitor resistance | |
| JP2023500950A (ja) | マントル細胞リンパ腫（ｍｃｌ）対象を特定するための鉄スコアおよびインビトロ方法ならびに治療的使用および方法 | |
| CN111433375B (zh) | 选择针对癌症患者的治疗的方法 | |
| WO2009021674A1 (en) | Predictive markers for egfr inhibitor treatment | |
| JP7122016B2 (ja) | グリオーマの予後、遠隔部再発リスク及び浸潤を判定する方法及びキット並びにグリオーマを処置するための医薬組成物 | |
| JP6478417B2 (ja) | 大腸癌患者の生存を予測及び改善するための方法 | |
| KR102431271B1 (ko) | 항암제 반응성 예측용 바이오마커 및 이의 용도 | |
| KR20240023045A (ko) | 암 치료를 위한 진단 방법 및 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181210 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181210 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200127 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200427 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200625 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200713 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6735277 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |